N/A
Completed N=107
Evaluation of a Crowd-Powered Web Platform for Depression and Anxiety
Depression, Anxiety
Source: ClinicalTrials.gov NCT04226742 ↗
Enrolled (actual)
107
Serious AEs
0.0%
Results posted
May 2023
Primary outcomePrimary: Depression Scores at Week 16 — 15.7; 15.7 score on a scale — p=0.79
Summary
100 participants will be enrolled in a two-armed randomized controlled trial of the Accumulated Depression and Anxiety Plans and Treatments (ADAPT) platform which integrates internet Cognitive Behavioral Therapy (iCBT) to determine impact on symptoms of depression and anxiety. This trial will pilot the effectiveness of the ADAPT platform, and evaluate the extent to which the ADAPT platform engages putative targets of personal relevance, skills use, and skills mastery.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Depression Scores at Week 16 |
15.7; 15.7 | 0.79 |
| PRIMARY Anxiety Scores at 16 Weeks |
12.4; 11.0 | .61 |
| SECONDARY Cognitive and Behavioral Skills Scores at 16 Weeks |
2.03; 1.78 | 0.088 |
| SECONDARY Self-efficacy Scores at 16 Weeks |
134.0; 124.0 | 0.142 |
| SECONDARY Accountability Scores at 16 Weeks |
75.1; 74.7 | 0.109 |
| SECONDARY Social Functioning Scores at 16 Weeks |
78.4; 79.3 | 0.736 |
Eligibility Criteria
Inclusion Criteria
- 1) Completion of the Mental Health America Screening to Supports (MHA S2S) or significant mood and anxiety symptoms as defined by an accepted cut-off on a validated measure the Depression Anxiety and Stress Scale (DASS). The accepted cut-off is scores greater than 22;
- 2) able to speak and read English;
- 3) at least 18 years of age.
Exclusion Criteria
- 1) severe suicidality (has ideation, plan, and intent)
Data sourced from ClinicalTrials.gov (NCT04226742). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.